Change Healthcare Inc. (Nasdaq: CHNG) (the “Company” or “Change Healthcare”), a leading healthcare technology company, today reported financial results for the fourth quarter and fiscal year ended March 31, 2021.
“The fourth quarter performance demonstrates the execution of our growth strategy, delivering on our financial objectives while continuing to make investments to support our customers and employees, and advance our capabilities,” said Neil de Crescenzo, president and chief executive officer. “As we enter fiscal 2022, we remain focused on delivering the next phase of growth by advancing our technology-first approach to innovation and further integrating our diverse capabilities to advance connectivity, enhance efficiency, and drive better experiences and outcomes throughout the healthcare industry.”
Fiscal 2021 Fourth Quarter Highlights:
Financial Summary
- Total revenue of $855.2 million, including solutions revenue of $804.3 million
- Net loss of $13.1 million, resulting in net loss of $0.04 per diluted share
- Adjusted net income of $134.0 million, resulting in adjusted net income of $0.42 per diluted share
- Adjusted EBITDA of $272.0 million
Recent Business Highlights
- Announced in collaboration with AWS a new Data Science as a Service (DSaaS) offering to drive improved outcomes and healthcare economics for vulnerable health communities
- Awarded “Best in KLAS” for Provider Eligibility Enrollment Services and for Payer IT Consulting Services
Impact of McKesson Exit on Comparability of Results
On March 10, 2020, Change Healthcare Inc. acquired the interest in Change Healthcare LLC (“the Joint Venture”) previously held by McKesson. The transaction resulted in Change Healthcare Inc. acquiring control of the Joint Venture, which was accounted for as a business combination and resulted in a new basis of accounting, and all of the business activities of the Joint Venture are now reported by the Company. Change Healthcare Inc.’s financial statements for periods prior to the acquisition were primarily limited to the equity method investment in the Joint Venture, and therefore did not reflect revenue, adjusted EBITDA, and other key measures. As a result, Change Healthcare Inc. does not consider comparison of the current operating results to the reported results for the same period in the prior year to be meaningful, and instead will compare our current quarter results to the prior quarter results of the Joint Venture, which have been recast to reflect the current segment structure, including the allocation of all corporate costs to the business units. This press release includes supplemental information for the recast results of the Joint Venture for the three months and year ended March 31, 2021. The recast results for all quarters in fiscal year 2019 and fiscal year 2020 are available in the appendix to the earnings presentation and will be included as an exhibit to Change Healthcare Inc.’s Form 10-K.
Financial Results for Fourth Quarter of Fiscal 2021
- Solutions revenue was $804.3 million for the current period, inclusive of the impact of the fair value adjustment to deferred revenue resulting from the McKesson exit, which reduced revenue recognized in the quarter by $10.1 million. Total revenue, which includes postage revenue, was $855.2 million. For the fourth quarter of fiscal 2020, the Joint Venture reported $786.6 million of solutions revenue and $843.4 million of total revenue. Solutions revenue for the current period reflects the $10.7 million net favorable impact of acquisitions and divestitures including the negative $6.9 million impact during the quarter from the divestiture of the Capacity Management business which closed on December 2, 2020.
- Net loss was $13.1 million, resulting in net loss of $0.04 per diluted share. For the fourth quarter of fiscal 2020, the Joint Venture reported net loss of $108.6 million or $0.34 per diluted unit. Net loss for the current period was positively impacted by new sales volumes, productivity improvements and cost initiatives.
- Adjusted net income was $134.0 million, resulting in adjusted net income of $0.42 per diluted share. For the fourth quarter of fiscal 2020, the Joint Venture reported adjusted net income of $133.2 million or $0.42 per diluted unit. Net loss per diluted share and adjusted net income per diluted share for the current period is based on 321 million shares compared to 320 million units in the prior year period.
- Adjusted EBITDA was $272.0 million for the current period. For the fourth quarter of fiscal 2020, the Joint Venture reported adjusted EBITDA of $264.4 million. The results in the current quarter reflect continued productivity and synergy realization.
Cash Flow and Balance Sheet Highlights
Net cash provided by operating activities was $586.2 million, free cash flow was $339.8 million, and adjusted free cash flow was $429.9 million, in each case, for the twelve months ended March 31, 2021. For the twelve months ended March 31, 2020, the Joint Venture reported net cash provided by operating activities, free cash flow, and adjusted free cash flow of $593.3 million, $334.7 million, and $481.5 million, respectively.
Net cash provided by operating activities, free cash flow, and adjusted free cash flow each is affected by pass-thru funds we receive from certain pharmaceutical industry participants in advance of our obligation to remit these funds to participating retail pharmacies. Such pass-thru funds on hand decreased by $12.8 million in the twelve months ended March 31, 2021, reducing free cash flow for the period by that amount, and increased by $21.7 million for the Joint Venture for the twelve months ended March 31, 2020. Net cash flow from operating activities, free cash flow, and adjusted free cash flow in the current period reflect working capital improvements driven by strong collections.
The Company ended the quarter with approximately $113.1 million of cash and cash equivalents, and approximately $4,762.1 million of total debt. During the current period, the Company repaid $50.0 million on its Term Loan Facility.
Proposed Merger with OptumInsight
On January 5, 2021, OptumInsight, a diversified health services company and part of UnitedHealth Group, and Change Healthcare agreed to combine (the “Merger”). Under the terms of the merger agreement, UnitedHealth Group, through a wholly-owned subsidiary, will acquire all of the outstanding shares of Change Healthcare common stock for $25.75 per share in cash. The Boards of Directors of both UnitedHealth Group and Change Healthcare have unanimously approved the terms of the Merger. At a special meeting held April 13, 2021, Change Healthcare stockholders voted to approve the Merger. Of the approximately 222 million shares voted, 99.9% voted in favor of the adoption of the merger agreement. The closing of the Merger is subject to applicable regulatory approval and other customary closing conditions.
Guidance
Due to the recently announced transaction with OptumInsight, we will no longer be providing financial guidance.
Webcast Information
Change Healthcare will host a conference call on Thursday, May 27, 2021, at 8:00 a.m. ET. Due to the previously announced transaction with OptumInsight, the Company will not be taking questions during the conference call.
Investors and other interested parties are invited to listen to the conference call via the Company's website at https://ir.changehealthcare.com/. The webcast will be available for on-demand listening at the aforementioned URL until May 27, 2022.
About Change Healthcare
Change Healthcare (Nasdaq: CHNG) is a leading healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system. Learn more at changehealthcare.com.
CHNG-IR
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations and businesses of Change Healthcare. Some of these statements can be identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “could,” “should,” “may,” “plan,” “project,” “predict” and similar expressions. Change Healthcare cautions readers of this press release that such “forward looking statements,” including without limitation, those relating to the timing of the proposed merger and Change Healthcare’s future business prospects, revenue, working capital, liquidity, capital needs, interest costs and income, wherever they occur in this press release or in other statements attributable to Change Healthcare, are necessarily estimates reflecting the judgment of Change Healthcare’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward looking statements.”
Factors that could cause Change Healthcare’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to, the inability to complete the proposed merger due to the failure to satisfy conditions to completion of the proposed merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; risks related to disruption of management’s attention from Change Healthcare’s ongoing business operations due to the transaction; the effect of the announcement of the proposed merger on Change Healthcare’s relationships with its customers, operating results and business generally; the risk that the proposed merger will not be consummated in a timely manner; exceeding the expected costs of the merger; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; macroeconomic and industry trends and adverse developments in the debt, consumer credit and financial services markets; uncertainty and risks related to the impact of the COVID-19 pandemic on the national and global economy, Change Healthcare’s business, suppliers, customers, and employees; Change Healthcare’s ability to retain or renew existing customers and attract new customers; Change Healthcare’s ability to connect a large number of payers and providers; Change Healthcare’s ability to provide competitive services and prices while maintaining its margins; further consolidation in end-customer markets; Change Healthcare’s ability to effectively manage costs; Change Healthcare’s ability to effectively develop and maintain relationships with channel partners; Change Healthcare’s ability to timely develop new services and the market’s willingness to adopt new services; Change Healthcare’s ability to deliver services timely without interruption; a decline in transaction volume in the U.S. healthcare industry; Change Healthcare’s ability to maintain access to its data sources; Change Healthcare’s ability to maintain the security and integrity of its data; Change Healthcare’s reliance on key management personnel; Change Healthcare’s ability to manage and expand its operations and keep up with rapidly changing technologies; the ability of outside service providers and key vendors to fulfill their obligations to Change Healthcare; risks related to international operations; Change Healthcare’s ability to protect and enforce its intellectual property, trade secrets and other forms of unpatented intellectual property; Change Healthcare’s ability to defend its intellectual property from infringement claims by third parties; government regulation and changes in the regulatory environment; changes in local, state, federal and international laws and regulations, including related to taxation; economic and political instability in the U.S. and international markets where Change Healthcare operates; litigation or regulatory proceedings; losses against which Change Healthcare does not insure; Change Healthcare’s ability to make acquisitions and integrate the operations of acquired businesses; Change Healthcare’s ability to make timely payments of principal and interest on its indebtedness; Change Healthcare’s ability to satisfy covenants in the agreements governing its indebtedness; Change Healthcare’s ability to maintain liquidity; our adoption of new, or amendments to existing, accounting standards, and other risks. For a more detailed discussion of these factors, see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Change Healthcare’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on June 4, 2020, as such factors may be updated from time to time in our periodic filings with the SEC, including in Change Healthcare’s most recent Quarterly Report on Form 10-Q filed with the SEC on February 4, 2021.
Change Healthcare’s forward-looking statements speak only as of the date of this press release or as of the date they are made. Change Healthcare disclaims any intent or obligation to update any “forward looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.
Non-GAAP Financial Measures
In the Company’s earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. We believe such measures provide supplemental information to investors with regards to our operating performance and assist investors’ ability to compare our financial results to those of other companies in the same industry. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this press release after the consolidated financial statements. These non-GAAP financial measures are calculated and presented on the basis of methodologies other than in accordance with GAAP. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP and may be defined and calculated differently by others in the same industry.
Consolidated Statements of Operations |
||||||||||||
(unaudited and amounts in thousands, except share and per share amounts) |
||||||||||||
|
||||||||||||
|
|
Three Months Ended March 31, |
||||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. |
|
Change
|
||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|||
Solutions revenue |
|
$ |
804,299 |
|
|
$ |
184,161 |
|
|
$ |
786,589 |
|
Postage revenue |
|
|
50,861 |
|
|
|
12,631 |
|
|
|
56,791 |
|
Total revenue |
|
|
855,160 |
|
|
|
196,792 |
|
|
|
843,380 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||
Cost of operations (exclusive of depreciation and amortization below) |
|
|
357,506 |
|
|
|
71,435 |
|
|
|
346,977 |
|
Research and development |
|
|
58,926 |
|
|
|
11,559 |
|
|
|
53,257 |
|
Sales, marketing, general and administrative |
|
|
187,606 |
|
|
|
37,389 |
|
|
|
175,725 |
|
Customer postage |
|
|
50,861 |
|
|
|
12,631 |
|
|
|
56,791 |
|
Depreciation and amortization |
|
|
154,495 |
|
|
|
30,838 |
|
|
|
89,852 |
|
Accretion and changes in estimate with related parties, net |
|
|
2,744 |
|
|
|
(31,349 |
) |
|
|
4,627 |
|
Gain on sale of businesses |
|
|
1,344 |
|
|
|
— |
|
|
|
— |
|
Tax receivable agreement charge |
|
|
— |
|
|
|
164,633 |
|
|
|
164,633 |
|
Goodwill impairment charge |
|
|
— |
|
|
|
561,164 |
|
|
|
— |
|
Total operating expenses |
|
|
813,482 |
|
|
|
858,300 |
|
|
|
891,862 |
|
Operating income (loss) |
|
|
41,678 |
|
|
|
(661,508 |
) |
|
|
(48,482 |
) |
Non-operating (income) and expense |
|
|
|
|
|
|
|
|
|
|||
Interest expense, net |
|
|
59,508 |
|
|
|
16,248 |
|
|
|
64,084 |
|
Contingent consideration |
|
|
— |
|
|
|
— |
|
|
|
(1,900 |
) |
Loss on extinguishment of debt |
|
|
1,289 |
|
|
|
— |
|
|
|
561 |
|
Loss from Equity Method Investment in the Joint Venture |
|
|
— |
|
|
|
276,216 |
|
|
|
— |
|
(Gain) loss on forward purchase contract |
|
|
— |
|
|
|
55,768 |
|
|
|
— |
|
Other, net |
|
|
(2,253 |
) |
|
|
(169 |
) |
|
|
(3,749 |
) |
Total non-operating (income) and expense |
|
|
58,544 |
|
|
|
348,063 |
|
|
|
58,996 |
|
Income (loss) before income tax provision (benefit) |
|
|
(16,866 |
) |
|
|
(1,009,571 |
) |
|
|
(107,478 |
) |
Income tax provision (benefit) |
|
|
(3,776 |
) |
|
|
(142,690 |
) |
|
|
1,112 |
|
Net income (loss) |
|
$ |
(13,090 |
) |
|
$ |
(866,881 |
) |
|
$ |
(108,590 |
) |
|
|
|
|
|
|
|
|
|
|
|||
Net income (loss) per common share: |
|
|
|
|
|
|
|
|
|
|||
Basic and diluted |
|
$ |
(0.04 |
) |
|
$ |
(1.64 |
) |
|
$ |
(0.34 |
) |
Weighted average common shares outstanding: (1) |
|
|
|
|
|
|
|
|
|
|||
Basic and diluted |
|
|
321,393,600 |
|
|
|
186,342,936 |
|
|
|
319,789,840 |
|
(1) |
Prior to the McKesson exit common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson. |
Consolidated Statements of Operations |
||||||||||||
(unaudited and amounts in thousands, except share and per share amounts) |
||||||||||||
|
||||||||||||
|
|
Year Ended March 31, |
||||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. |
|
Change
|
||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|||
Solutions revenue |
|
$ |
2,893,889 |
|
|
$ |
184,161 |
|
|
$ |
3,074,894 |
|
Postage revenue |
|
|
196,532 |
|
|
|
12,631 |
|
|
|
228,079 |
|
Total revenue |
|
|
3,090,421 |
|
|
|
196,792 |
|
|
|
3,302,973 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|||
Cost of operations (exclusive of depreciation and amortization below) |
|
|
1,335,075 |
|
|
|
71,435 |
|
|
|
1,345,920 |
|
Research and development |
|
|
227,036 |
|
|
|
11,559 |
|
|
|
205,035 |
|
Sales, marketing, general and administrative |
|
|
686,645 |
|
|
|
39,893 |
|
|
|
743,311 |
|
Customer postage |
|
|
196,532 |
|
|
|
12,631 |
|
|
|
228,079 |
|
Depreciation and amortization |
|
|
591,048 |
|
|
|
30,838 |
|
|
|
315,946 |
|
Accretion and changes in estimate with related parties, net |
|
|
13,158 |
|
|
|
15,823 |
|
|
|
14,966 |
|
Gain on sale of businesses |
|
|
(59,143 |
) |
|
|
— |
|
|
|
— |
|
Tax receivable agreement charge |
|
|
— |
|
|
|
164,633 |
|
|
|
164,633 |
|
Goodwill impairment charge |
|
|
— |
|
|
|
561,164 |
|
|
|
— |
|
Total operating expenses |
|
|
2,990,351 |
|
|
|
907,976 |
|
|
|
3,017,890 |
|
Operating income (loss) |
|
|
100,070 |
|
|
|
(711,184 |
) |
|
|
285,083 |
|
Non-operating (income) and expense |
|
|
|
|
|
|
|
|
|
|||
Interest expense, net |
|
|
245,241 |
|
|
|
16,652 |
|
|
|
283,745 |
|
Contingent consideration |
|
|
(3,000 |
) |
|
|
— |
|
|
|
(91 |
) |
Loss on extinguishment of debt |
|
|
8,924 |
|
|
|
— |
|
|
|
19,975 |
|
Loss from Equity Method Investment in the Joint Venture |
|
|
— |
|
|
|
380,713 |
|
|
|
— |
|
(Gain) loss on forward purchase contract |
|
|
— |
|
|
|
(15,881 |
) |
|
|
— |
|
Other, net |
|
|
(3,698 |
) |
|
|
(1,817 |
) |
|
|
(14,630 |
) |
Total non-operating (income) and expense |
|
|
247,467 |
|
|
|
379,667 |
|
|
|
288,999 |
|
Income (loss) before income tax provision (benefit) |
|
|
(147,397 |
) |
|
|
(1,090,851 |
) |
|
|
(3,916 |
) |
Income tax provision (benefit) |
|
|
(35,187 |
) |
|
|
(143,254 |
) |
|
|
1,701 |
|
Net income (loss) |
|
$ |
(112,210 |
) |
|
$ |
(947,597 |
) |
|
$ |
(5,617 |
) |
|
|
|
|
|
|
|
|
|
|
|||
Net income (loss) per common share: |
|
|
|
|
|
|
|
|
|
|||
Basic and diluted |
|
$ |
(0.35 |
) |
|
$ |
(6.92 |
) |
|
$ |
(0.02 |
) |
Weighted average common shares outstanding: (1) |
|
|
|
|
|
|
|
|
|
|||
Basic and diluted |
|
|
320,771,789 |
|
|
|
136,996,624 |
|
|
|
302,412,870 |
|
(1) |
Prior to the McKesson exit common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson. |
Consolidated Balance Sheets |
||||||||
(unaudited and amounts in thousands, except share and per share amounts) |
||||||||
|
||||||||
|
|
March 31, 2021 |
|
March 31, 2020 |
||||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
113,101 |
|
|
$ |
410,405 |
|
Accounts receivable, net |
|
|
732,614 |
|
|
|
740,105 |
|
Contract assets, net |
|
|
132,856 |
|
|
|
132,704 |
|
Prepaid expenses and other current assets |
|
|
140,258 |
|
|
|
117,967 |
|
Total current assets |
|
|
1,118,829 |
|
|
|
1,401,181 |
|
Property and equipment, net |
|
|
174,370 |
|
|
|
206,196 |
|
Operating lease right-of-use assets, net |
|
|
93,412 |
|
|
|
— |
|
Goodwill |
|
|
4,108,792 |
|
|
|
3,795,325 |
|
Intangible assets, net |
|
|
4,187,072 |
|
|
|
4,365,806 |
|
Investment in business purchase option |
|
|
— |
|
|
|
146,500 |
|
Other noncurrent assets, net |
|
|
430,141 |
|
|
|
192,372 |
|
Total assets |
|
$ |
10,112,616 |
|
|
$ |
10,107,380 |
|
Liabilities |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
57,449 |
|
|
$ |
68,169 |
|
Accrued expenses |
|
|
484,293 |
|
|
|
390,294 |
|
Deferred revenue |
|
|
436,666 |
|
|
|
302,313 |
|
Due to related parties, net |
|
|
10,766 |
|
|
|
20,234 |
|
Current portion of long-term debt |
|
|
27,339 |
|
|
|
278,779 |
|
Current portion of operating lease liabilities |
|
|
30,608 |
|
|
|
— |
|
Total current liabilities |
|
|
1,047,121 |
|
|
|
1,059,789 |
|
Long-term debt, excluding current portion |
|
|
4,734,775 |
|
|
|
4,710,294 |
|
Long-term operating lease liabilities |
|
|
75,396 |
|
|
|
— |
|
Deferred income tax liabilities |
|
|
605,291 |
|
|
|
615,904 |
|
Tax receivable agreement obligations to related parties |
|
|
103,151 |
|
|
|
177,826 |
|
Tax receivable agreement obligations |
|
|
229,082 |
|
|
|
164,633 |
|
Other long-term liabilities |
|
|
65,572 |
|
|
|
93,487 |
|
Total liabilities |
|
|
6,860,388 |
|
|
|
6,821,933 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' Equity |
|
|
|
|
|
|
||
Common Stock (par value, $.001), 9,000,000,000 and 9,000,000,000 shares authorized and 306,796,076 and 303,428,142 shares issued and outstanding at March 31, 2021 and 2020, respectively |
|
|
307 |
|
|
|
303 |
|
Preferred stock (par value, $.001), 900,000,000 shares authorized and no shares issued and outstanding at both March 31, 2021 and 2020 |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
4,283,391 |
|
|
|
4,222,580 |
|
Accumulated other comprehensive income (loss) |
|
|
11,221 |
|
|
|
(7,372 |
) |
Accumulated deficit |
|
|
(1,042,691 |
) |
|
|
(930,064 |
) |
Total stockholders' equity |
|
|
3,252,228 |
|
|
|
3,285,447 |
|
Total liabilities and stockholders' equity |
|
$ |
10,112,616 |
|
|
$ |
10,107,380 |
|
Consolidated Statements of Cash Flows |
||||||||||||
(unaudited and amounts in thousands) |
||||||||||||
|
||||||||||||
|
|
Year Ended March 31, |
|
|
|
|||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. |
|
Change
|
||||||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|||
Net income (loss) |
|
$ |
(112,210 |
) |
|
$ |
(947,597 |
) |
|
$ |
(5,617 |
) |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
|
|||
Depreciation and amortization |
|
|
591,048 |
|
|
|
30,838 |
|
|
|
315,946 |
|
Amortization of capitalized software developed for sale |
|
|
1,326 |
|
|
|
— |
|
|
|
14,415 |
|
Accretion and changes in estimate, net |
|
|
11,644 |
|
|
|
15,823 |
|
|
|
14,966 |
|
Equity compensation |
|
|
59,016 |
|
|
|
1,701 |
|
|
|
31,808 |
|
Deferred income tax expense (benefit) |
|
|
(50,114 |
) |
|
|
(143,822 |
) |
|
|
(2,613 |
) |
Amortization of debt discount and issuance costs |
|
|
32,532 |
|
|
|
2,235 |
|
|
|
18,807 |
|
Contingent consideration |
|
|
(3,000 |
) |
|
|
— |
|
|
|
(91 |
) |
Gain on sale of businesses |
|
|
(59,143 |
) |
|
|
— |
|
|
|
— |
|
Loss on extinguishment of debt |
|
|
8,924 |
|
|
|
— |
|
|
|
19,975 |
|
(Gain) loss on other investments |
|
|
— |
|
|
|
(15,881 |
) |
|
|
— |
|
Non-cash lease expense |
|
|
29,114 |
|
|
|
— |
|
|
|
— |
|
Goodwill impairment charge |
|
|
— |
|
|
|
561,164 |
|
|
|
— |
|
Loss from Equity Method Investment in the Joint Venture |
|
|
— |
|
|
|
380,713 |
|
|
|
— |
|
Tax receivable agreement charge |
|
|
— |
|
|
|
164,633 |
|
|
|
164,633 |
|
Other, net |
|
|
11,257 |
|
|
|
(1,110 |
) |
|
|
6,896 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|||
Accounts receivable, net |
|
|
(6,064 |
) |
|
|
(21,211 |
) |
|
|
(1,267 |
) |
Contract assets, net |
|
|
158 |
|
|
|
— |
|
|
|
21,390 |
|
Prepaid expenses and other assets |
|
|
(87,540 |
) |
|
|
(6,219 |
) |
|
|
(29,375 |
) |
Accounts payable |
|
|
(21,407 |
) |
|
|
7,532 |
|
|
|
(16,609 |
) |
Accrued expenses and other liabilities |
|
|
14,178 |
|
|
|
(195,207 |
) |
|
|
10,929 |
|
Deferred revenue |
|
|
166,477 |
|
|
|
11,304 |
|
|
|
32,648 |
|
Due to the Joint Venture, net |
|
|
— |
|
|
|
1,176 |
|
|
|
— |
|
Due to related party, net |
|
|
— |
|
|
|
— |
|
|
|
(3,532 |
) |
Net cash provided by (used in) operating activities |
|
|
586,196 |
|
|
|
(153,928 |
) |
|
|
593,309 |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|||
Capitalized expenditures |
|
|
(246,381 |
) |
|
|
(13,002 |
) |
|
|
(258,576 |
) |
Acquisitions, net of cash acquired |
|
|
(439,483 |
) |
|
|
330,667 |
|
|
|
(18,994 |
) |
Proceeds from sale of businesses |
|
|
115,733 |
|
|
|
— |
|
|
|
— |
|
Proceeds from sale of real estate |
|
|
— |
|
|
|
— |
|
|
|
29,837 |
|
Investment in the Joint Venture |
|
|
— |
|
|
|
(610,784 |
) |
|
|
— |
|
Investment in debt and equity securities of the Joint Venture |
|
|
— |
|
|
|
(278,875 |
) |
|
|
— |
|
Other, net |
|
|
2,099 |
|
|
|
7,332 |
|
|
|
(2 |
) |
Net cash provided by (used in) investing activities |
|
|
(568,032 |
) |
|
|
(564,662 |
) |
|
|
(247,735 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|||
Payments on Revolving Facility |
|
|
(250,000 |
) |
|
|
— |
|
|
|
— |
|
Proceeds from Revolving Facility |
|
|
— |
|
|
|
250,000 |
|
|
|
250,000 |
|
Payments on Term Loan Facility |
|
|
(315,000 |
) |
|
|
— |
|
|
|
(1,087,750 |
) |
Proceeds from issuance of Senior Notes |
|
|
325,000 |
|
|
|
— |
|
|
|
— |
|
Payments under tax receivable agreements |
|
|
(20,691 |
) |
|
|
— |
|
|
|
(27,227 |
) |
Receipts (payments) on derivative instruments |
|
|
(29,538 |
) |
|
|
(890 |
) |
|
|
935 |
|
Employee tax withholding on vesting of equity compensation awards |
|
|
(4,108 |
) |
|
|
— |
|
|
|
— |
|
Payments on deferred financing obligations |
|
|
(19,519 |
) |
|
|
— |
|
|
|
(6,593 |
) |
Payment of senior amortizing notes |
|
|
(15,636 |
) |
|
|
(11,094 |
) |
|
|
— |
|
Payment of debt issued to Change Healthcare Inc. |
|
|
— |
|
|
|
— |
|
|
|
(7,332 |
) |
Proceeds from exercise of equity awards |
|
|
17,514 |
|
|
|
— |
|
|
|
— |
|
Capital contribution from Members from exercise of equity compensation awards |
|
|
— |
|
|
|
— |
|
|
|
6,256 |
|
Proceeds from initial public offering, net of issuance costs |
|
|
— |
|
|
|
608,679 |
|
|
|
— |
|
Proceeds from Change Healthcare Inc. initial public offering |
|
|
— |
|
|
|
— |
|
|
|
608,679 |
|
Proceeds from issuance of debt component of tangible equity units |
|
|
— |
|
|
|
47,367 |
|
|
|
— |
|
Proceeds from debt issued to Change Healthcare Inc. |
|
|
— |
|
|
|
— |
|
|
|
47,367 |
|
Proceeds from issuance of equity component of tangible equity units, net of issuance costs |
|
|
— |
|
|
|
232,929 |
|
|
|
— |
|
Proceeds from forward purchase contract with Change Healthcare Inc. |
|
|
— |
|
|
|
— |
|
|
|
232,929 |
|
Other, net |
|
|
(6,800 |
) |
|
|
(1,421 |
) |
|
|
(3,024 |
) |
Net cash provided by (used in) financing activities |
|
|
(318,778 |
) |
|
|
1,125,570 |
|
|
|
14,240 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
3,310 |
|
|
|
16 |
|
|
|
(1,021 |
) |
Net increase (decrease) in cash and cash equivalents |
|
|
(297,304 |
) |
|
|
406,996 |
|
|
|
358,793 |
|
Cash and cash equivalents at beginning of period |
|
|
410,405 |
|
|
|
3,409 |
|
|
|
48,894 |
|
Cash and cash equivalents at end of period |
|
$ |
113,101 |
|
|
$ |
410,405 |
|
|
$ |
407,687 |
|
Reconciliation of Net Income (Loss) to Adjusted EBITDA |
||||||||||||
(unaudited and amounts in thousands) |
||||||||||||
|
||||||||||||
|
|
Three Months Ended March 31, |
||||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. (1) |
|
Change
|
||||||||
Net income (loss) |
|
$ |
(13,090 |
) |
$ |
(866,881 |
) |
|
$ |
(108,590 |
) |
|
Income tax provision (benefit) |
|
|
(3,776 |
) |
|
|
(142,690 |
) |
|
|
1,112 |
|
Income (loss) before income tax provision (benefit) |
|
|
(16,866 |
) |
|
|
(1,009,571 |
) |
|
|
(107,478 |
) |
Amortization of capitalized software developed for sale |
|
|
776 |
|
|
|
|
|
|
3,959 |
|
|
Depreciation and amortization |
|
|
154,495 |
|
|
|
|
|
|
89,852 |
|
|
Interest expense, net |
|
|
59,508 |
|
|
|
|
|
|
64,084 |
|
|
Equity compensation |
|
|
24,158 |
|
|
|
|
|
|
6,893 |
|
|
Acquisition accounting adjustments |
|
|
5,917 |
|
|
|
|
|
|
522 |
|
|
Acquisition and divestiture-related costs |
|
|
9,590 |
|
|
|
|
|
|
1,664 |
|
|
Integration and related costs |
|
|
13,094 |
|
|
|
|
|
|
15,131 |
|
|
Strategic initiatives, duplicative and transition costs |
|
|
8,671 |
|
|
|
|
|
|
8,991 |
|
|
Severance costs |
|
|
2,717 |
|
|
|
|
|
|
7,824 |
|
|
Accretion and changes in estimate, net |
|
|
3,215 |
|
|
|
|
|
|
4,627 |
|
|
Management fees and related costs |
|
|
— |
|
|
|
|
|
|
2,647 |
|
|
Impairment of long-lived assets and other |
|
|
3,772 |
|
|
|
|
|
|
1,347 |
|
|
Tax receivable agreement charge |
|
|
— |
|
|
|
|
|
|
164,633 |
|
|
Gain on sale of business |
|
|
1,344 |
|
|
|
|
|
|
— |
|
|
Contingent consideration |
|
|
— |
|
|
|
|
|
|
(1,900 |
) |
|
Loss on extinguishment of debt |
|
|
1,289 |
|
|
|
|
|
|
560 |
|
|
Other non-routine, net |
|
|
365 |
|
|
|
|
|
|
1,002 |
|
|
Adjusted EBITDA |
|
$ |
272,045 |
|
|
|
|
|
$ |
264,358 |
|
|
(1) |
Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted EBITDA as a key performance metric, therefore we have not presented a reconciliation to adjusted EBITDA for the three months ended March 31, 2020. |
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) |
||||||||||||
(unaudited and amounts in thousands, except share and per share amounts) |
||||||||||||
|
||||||||||||
|
|
Three Months Ended March 31, |
||||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. (1) |
|
Change
|
||||||||
Net income (loss) |
|
$ |
(13,090 |
) |
|
$ |
(866,881 |
) |
|
$ |
(108,590 |
) |
Amortization expense resulting from acquisition method adjustments |
|
|
117,362 |
|
|
|
|
|
|
35,251 |
|
|
EBITDA adjustments |
|
|
74,132 |
|
|
|
|
|
|
213,942 |
|
|
Tax effect of EBITDA adjustments and amortization expense |
|
|
(44,413 |
) |
|
|
|
|
|
(7,417 |
) |
|
Adjusted net income (loss) |
|
$ |
133,991 |
|
|
|
|
|
$ |
133,186 |
|
|
|
|
|
|
|
|
|
|
|
|
|||
Adjusted net income (loss) per diluted share (2) |
|
$ |
0.42 |
|
|
|
|
|
$ |
0.42 |
|
|
|
||||||||||||
|
|
Year Ended March 31, |
||||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. (1) |
|
Change
|
||||||||
Net income (loss) |
|
$ |
(112,210 |
) |
|
$ |
(947,597 |
) |
|
$ |
(5,617 |
) |
Amortization expense resulting from acquisition method adjustments |
|
|
463,334 |
|
|
|
|
|
|
139,875 |
|
|
EBITDA adjustments |
|
|
243,947 |
|
|
|
|
|
|
385,542 |
|
|
Tax effect of EBITDA adjustments and amortization expense |
|
|
(166,324 |
) |
|
|
|
|
|
(52,168 |
) |
|
Adjusted net income (loss) |
|
$ |
428,747 |
|
|
|
|
|
$ |
467,632 |
|
|
|
|
|
|
|
|
|
|
|
|
|||
Adjusted net income (loss) per diluted share (2) |
|
$ |
1.34 |
|
|
|
|
|
$ |
1.55 |
|
|
(1) |
Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted net income (loss) as a key performance metric, therefore we have not presented a reconciliation to adjusted net income (loss) for the three months and year ended March 31, 2020. |
(2) |
Prior to the McKesson exit, Common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson. |
Segment Results |
||||||||||
(unaudited and amounts in thousands) |
||||||||||
|
||||||||||
|
|
Three Months Ended March 31, |
||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||
|
|
Change Healthcare Inc. (1) |
|
Change
|
||||||
Segment revenue |
|
|
|
|
|
|
|
|
|
|
Software and Analytics |
|
$ |
416,265 |
|
|
|
N/A |
|
$ |
418,658 |
Network Solutions |
|
|
198,334 |
|
|
|
N/A |
|
|
152,163 |
Technology-Enabled Services |
|
|
227,311 |
|
|
|
N/A |
|
|
242,444 |
Postage and Eliminations (3) |
|
|
23,391 |
|
|
|
N/A |
|
|
30,115 |
Purchase Accounting Adjustment (4) |
|
|
(10,141 |
) |
|
|
N/A |
|
|
— |
Net revenue |
|
$ |
855,160 |
|
|
|
N/A |
|
$ |
843,380 |
|
|
|
|
|
|
|
|
|
|
|
Segment adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
Software and Analytics |
|
$ |
144,025 |
|
|
|
N/A |
|
$ |
150,341 |
Network Solutions |
|
|
108,147 |
|
|
|
N/A |
|
|
85,340 |
Technology-Enabled Services |
|
|
19,873 |
|
|
|
N/A |
|
|
28,677 |
Postage and Eliminations |
|
|
— |
|
|
|
N/A |
|
|
— |
Total adjusted EBITDA |
|
$ |
272,045 |
|
|
|
N/A |
|
$ |
264,358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended March 31, |
||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||
|
|
Change Healthcare Inc. (1) |
|
Change
|
||||||
Segment revenue |
|
|
|
|
|
|
|
|
|
|
Software and Analytics |
|
$ |
1,534,926 |
|
|
|
N/A |
|
$ |
1,612,800 |
Network Solutions |
|
|
717,843 |
|
|
|
N/A |
|
|
588,748 |
Technology-Enabled Services |
|
|
869,349 |
|
|
|
N/A |
|
|
978,684 |
Postage and Eliminations (3) |
|
|
96,533 |
|
|
|
N/A |
|
|
122,741 |
Purchase Accounting Adjustment (4) |
|
|
(128,230 |
) |
|
|
N/A |
|
|
— |
Net revenue |
|
$ |
3,090,421 |
|
|
|
N/A |
|
$ |
3,302,973 |
|
|
|
|
|
|
|
|
|
|
|
Segment adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
Software and Analytics |
|
$ |
526,129 |
|
|
|
N/A |
|
$ |
565,628 |
Network Solutions |
|
|
377,005 |
|
|
|
N/A |
|
|
331,659 |
Technology-Enabled Services |
|
|
31,031 |
|
|
|
N/A |
|
|
98,446 |
Postage and Eliminations |
|
|
— |
|
|
|
N/A |
|
|
— |
Total adjusted EBITDA |
|
$ |
934,165 |
|
|
|
N/A |
|
$ |
995,733 |
(1) |
Prior to the McKesson exit, Change Healthcare Inc. did not have revenues from customers and did not utilize adjusted EBITDA as a key performance metric. |
(2) |
The prior year results of Change Healthcare LLC have been retrospectively adjusted to be consistent with the Company’s current segment structure and cost allocation methodology. |
(3) |
Revenue for Postage and Eliminations includes postage revenue of $50.9 million for Change Healthcare Inc. for the three months ended March 31, 2021 and $56.8 million for Change Healthcare LLC for the three months ended March 31, 2020. Revenue for Postage and Eliminations includes postage revenue of $196.5 million for Change Healthcare Inc. for the year ended March 31, 2021 and $228.1 million for Change Healthcare LLC for the year ended March 31, 2020. |
(4) |
Amount reflects the impact to deferred revenue resulting from the McKesson exit which reduced revenue recognized during the three months and year ended March 31, 2021. |
|
Reconciliation of Cash Provided by (Used in) Operating Activities to Free Cash Flow and Adjusted Free Cash Flow |
||||||||||||
(unaudited and amounts in thousands) |
||||||||||||
|
||||||||||||
|
|
Year Ended March 31, |
||||||||||
|
|
2021 |
|
2020 |
|
2020 |
||||||
|
|
Change Healthcare Inc. (1) |
|
Change
|
||||||||
Cash provided by (used in) operating activities (2) |
|
$ |
586,196 |
|
|
$ |
(153,928 |
) |
|
$ |
593,309 |
|
Capital expenditures |
|
|
(246,381 |
) |
|
|
(13,002 |
) |
|
|
(258,576 |
) |
Free cash flow |
|
|
339,815 |
|
|
|
(166,930 |
) |
|
|
334,733 |
|
Adjustments to free cash flow (3): |
|
|
|
|
|
|
|
|
|
|||
Integration and related costs |
|
|
40,675 |
|
|
|
|
|
|
82,108 |
|
|
Strategic initiatives, duplicative and transition costs |
|
|
21,841 |
|
|
|
|
|
|
23,325 |
|
|
Severance costs |
|
|
13,184 |
|
|
|
|
|
|
22,113 |
|
|
Integration and strategic capital expenditures |
|
|
14,379 |
|
|
|
|
|
|
19,254 |
|
|
Adjusted free cash flow |
|
$ |
429,894 |
|
|
|
|
|
$ |
481,533 |
|
|
(1) |
Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted free cash flow as a key performance metric, therefore we have not presented a reconciliation to adjusted free cash flow for the year ended March 31, 2020. |
(2) |
Includes cash used by pass-thru funds of $12.8 million for Change Healthcare Inc. for the year ended March 31, 2021 and cash provided by pass-thru funds of $21.7 million for Change Healthcare LLC for the year ended March 31, 2020. |
(3) |
All operating costs and integration and strategic capital expenditures are presented on an as-incurred basis. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005947/en/
Contacts
Evan Smith, CFA
Investor Relations
404-338-2225
Evan.Smith@changehealthcare.com
Katherine Wojtecki
External Communications
630-624-9142
Katherine.Wojtecki@changehealthcare.com
